SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Skye Bioscience, Inc. ("Skye" or "the Company") (NASDAQ: SKYE) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Skye securities between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/SKYE.

Case Details

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Skye's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) nimacimab was less effective than Defendants had led investors to believe; (2) accordingly, nimacimab's clinical, regulatory, and commercial prospects were overstated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times.

What's Next?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/SKYE. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Skye you have until January 16, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | info@bgandg.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/skye-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-skye-bioscience-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302619747.html

SOURCE Bronstein, Gewirtz & Grossman, LLC